NCT04266730 — UNC Lineberger Comprehensive Cancer Center neoantigen vaccine trial
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
Registry record
| Registry ID | NCT04266730 ↗ |
|---|---|
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Suspended |
| Indication | Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck |
| Enrollment | 6 participants (target) |
| Start date | 2027-05-20 |
| Primary completion | 2027-06-01 (est.) |
| Last registry update | 23 Apr 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04266730), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
FAQ
What phase is NCT04266730?
NCT04266730 (Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab) is registered on ClinicalTrials.gov as Phase 1, sponsored by UNC Lineberger Comprehensive Cancer Center.
Is NCT04266730 recruiting?
As of the 2026-04-23 registry update, NCT04266730 is listed as "Suspended". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04266730?
The lead sponsor is UNC Lineberger Comprehensive Cancer Center.
What condition does NCT04266730 study?
The registered conditions are Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck. Primary completion is listed as 2027-06-01 (estimated).
Are results available for NCT04266730?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04266730.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.